YU
INZY

Yale University’s Inozyme Pharma INZY Stock Holding History

Yale University’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-113,502
Closed -$2.34M – 10
2020
Q4 		$2.34M Hold
113,502
– – 1.59% 6
2020
Q3 		$2.98M Buy
+113,502
New +$2.82M 9.13% 4

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Yale University's INZY Position: Q1 2021 in Review

Yale University sold out of Inozyme Pharma (INZY) in Q1 2021, closing a stake of 113,502 shares — an estimated $2.34M sold.

Yale University first reported a position in INZY in Q3 2020 and held it in 2 quarters. The position peaked at $2.98M in Q3 2020. 55 funds tracked by Wall St. Rank hold INZY as of Q1 2021.

  • Yale University reported no remaining Inozyme Pharma position as of Q1 2021 after selling out during the quarter.
  • Yale University sold 113,502 Inozyme Pharma shares in Q1 2021, an estimated $2.34M.
  • Yale University first reported a position in Inozyme Pharma in Q3 2020 and held it in 2 quarters.
  • Yale University's Inozyme Pharma position peaked at $2.98M in Q3 2020.
  • 55 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2021.

Based on Yale University's 13F filing for Q1 2021, filed 14 May 2021.